Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option
Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous gen...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/9945725 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849400736401588224 |
|---|---|
| author | Shuqi Qin Ning Dong Ming Yang Jialin Wang Xue Feng Yanling Wang |
| author_facet | Shuqi Qin Ning Dong Ming Yang Jialin Wang Xue Feng Yanling Wang |
| author_sort | Shuqi Qin |
| collection | DOAJ |
| description | Age-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD. |
| format | Article |
| id | doaj-art-8d70b9d89bc94593a7a6a36a6fda512b |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-8d70b9d89bc94593a7a6a36a6fda512b2025-08-20T03:37:56ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/99457259945725Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic OptionShuqi Qin0Ning Dong1Ming Yang2Jialin Wang3Xue Feng4Yanling Wang5Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaDepartment of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing, ChinaAge-related macular degeneration (AMD) is a multifactorial disease, which can culminate in irreversible vision loss and blindness in elderly. Nowadays, there is a big gap between dry AMD and wet AMD on treatment. Accounting for nearly 90% of AMD, dry AMD still lacks effective treatment. Numerous genetic and molecular researches have confirmed the significant role of the complement system in the pathogenesis of AMD, leading to a deeper exploration of complement inhibitors in the treatment of AMD. To date, at least 14 different complement inhibitors have been or are being explored in AMD in almost 40 clinical trials. While most complement inhibitors fail to treat AMD successfully, two of them are effective in inhibiting the rate of GA progression in phase II clinical trials, and both of them successfully entered phase III trials. Furthermore, recently emerging complement gene therapy and combination therapy also offer new opportunities to treat AMD in the future. In this review, we aim to introduce genetic and molecular associations between the complement system and AMD, provide the updated progress in complement inhibitors in AMD on clinical trials, and discuss the challenges and prospects of complement therapeutic strategies in AMD.http://dx.doi.org/10.1155/2021/9945725 |
| spellingShingle | Shuqi Qin Ning Dong Ming Yang Jialin Wang Xue Feng Yanling Wang Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option Journal of Immunology Research |
| title | Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option |
| title_full | Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option |
| title_fullStr | Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option |
| title_full_unstemmed | Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option |
| title_short | Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option |
| title_sort | complement inhibitors in age related macular degeneration a potential therapeutic option |
| url | http://dx.doi.org/10.1155/2021/9945725 |
| work_keys_str_mv | AT shuqiqin complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption AT ningdong complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption AT mingyang complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption AT jialinwang complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption AT xuefeng complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption AT yanlingwang complementinhibitorsinagerelatedmaculardegenerationapotentialtherapeuticoption |